Autres langues Verrica Pharmaceuticals Inc.

Actions

VRCA

US92511W1080

Temps réel estimé Cboe BZX Autres places de cotation 20:45:42 12/06/2024			Varia. 5j.	Varia. 1 janv.
8,885 ^USD	-0,50 %		-2,95 %	+21,31 %

15/05	Verrica Pharmaceuticals modifie son accord de licence avec Torii Pharmaceutical pour l'essai de phase 3 d'Ycanth	MT
15/05	Verrica Pharmaceuticals Inc. annonce la modification de l'accord de collaboration et de licence avec Torii Pharmaceutical Co. Ltd. pour financer un essai clinique pivot de phase 3 à l'échelle mondiale afin d'étudier Ycanth pour le traitement des verrues communes	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York	30/05
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York	30/05
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones	30/05
Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	15/05
Verrica Pharmaceuticals : Company Presentation	15/05
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts	15/05
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts	15/05
Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	15/05
Verrica Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q1 Revenue $3.8M, vs. Street Est of $2.7M	13/05
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results	13/05
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences	09/05
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024	08/05
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA	27/03
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	26/03
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA	26/03
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	26/03
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	09/03
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Verrica Pharmaceuticals Inc.

Actions

VRCA

US92511W1080

Autres langues

Filtres